# US 2016/0251364 A1 · Process for preparing oxycodone compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251364 A1
- Document ID: US20160251364A1
- Status: Published application
- Kind: A1
- Application number: 15/061,588
- Filed: 2016-03-04
- Published: 2016-09-01
- Earliest claimed: 2004-03-30
- Assignees: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes Technologies
- Applicants: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes Technologies
- Inventors: Robert Chapman; Lonn S. Rider; Qi Hong; Donald Kyle; Robert Kupper
- Web page: https://patentgrep.com/patent/US20160251364A1

## CPC

- C07D 489/08: Oxygen atom
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2095: {Tabletting processes}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 489/02: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
- C07D 489/04: Salts; Organic complexes
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

## Claims

### Claim at position 1

1-79. (canceled)

### Claim 80

A process for preparing an oxycodone salt composition comprising:
salting an oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone and 14-hydroxycodeinone to convert the oxycodone free base composition to an oxycodone salt composition,
promoting dehydration of 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during the salting by overloading the amount of an acid during the conversion,
providing reducing conditions sufficient for the 14-hydroxycodeinone to be reduced to oxycodone,
isolating the oxycodone salt composition, and
analyzing a sample of the oxycodone salt composition for the presence of 8α,14-dihydroxy-7,8-dihydrocodeinone and 14-hydroxycodeinone.

### Claim 81 (depends on 80)

The process of claim 80, wherein the reducing conditions sufficient for the 14-hydroxycodeinone to be reduced to oxycodone are provided by a catalyst and a hydrogen donor.

### Claim 82 (depends on 81)

The process of claim 81, wherein the hydrogen donor is selected from the group consisting of hydrogen gas, formic acid, indoline, cyclohexene, sodium borohydride, tetrahydroquinoline, 2,5-dihydrofuran, phosphoric acid, and combinations thereof.

### Claim 83 (depends on 81)

The process of claim 81, wherein the catalyst is selected from the group consisting of Raney cobalt, Raney nickel, palladium on carbon, platinum on carbon, palladium on alumina, platinum oxide, ruthenium on alumina, rhodium on alumina, and rhodium on carbon.

### Claim 84 (depends on 81)

The process of claim 81, wherein the catalyst is a noble metal catalyst.

### Claim 85 (depends on 81)

The process of claim 81, wherein the catalyst a palladium-carbon catalyst.

### Claim 86 (depends on 80)

The process of claim 80, wherein the oxycodone salt composition comprises less than 25 ppm of 14-hydroxycodeinone.

### Claim 87 (depends on 86)

The process of claim 86, wherein the oxycodone salt composition comprises less than 15 ppm of 14-hydroxycodeinone.

### Claim 88 (depends on 87)

The process of claim 87, wherein the oxycodone salt composition comprises less than 10 ppm of 14-hydroxycodeinone.

### Claim 89 (depends on 80)

The process of claim 80, wherein the oxycodone salt composition comprises less than 5 ppm of 14-hydroxycodeinone.

### Claim 90 (depends on 80)

The process of claim 80, wherein the oxycodone salt composition is isolated by a process comprising crystallization.

### Claim 91 (depends on 80)

The process of claim 80, wherein the acid is hydrochloric acid.

### Claim 92 (depends on 80)

The process of claim 80, wherein the process is for preparing an oxycodone hydrochloride salt composition.

### Claim 93 (depends on 92)

The process of claim 92, wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition.

### Claim 94

A process for preparing an oxycodone salt composition comprising:
salting an oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone and 14-hydroxycodeinone to convert the oxycodone free base composition to an oxycodone salt composition,
promoting dehydration of 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during the salting by overloading the amount of an acid during the conversion,
providing reducing conditions sufficient for the 14-hydroxycodeinone to be reduced to oxycodone,
isolating the oxycodone salt composition, and
analyzing a sample of the oxycodone salt composition for the presence of 8α,14-dihydroxy-7,8-dihydrocodeinone and 14-hydroxycodeinone,
wherein the sample of the oxycodone salt composition comprises greater than 100 ppm 14-hydroxycodeinone.

### Claim 95 (depends on 94)

The process of claim 94, further comprising hydrogenating the oxycodone salt composition to decrease the level of 14-hydroxycodeinone.

### Claim 96 (depends on 95)

The process of claim 95, wherein the level of 14-hydroxycodeinone is decreased to less than 100 pm.

### Claim 97 (depends on 96)

The process of claim 96, wherein the level of 14-hydroxycodeinone is decreased to less than 25 ppm.

### Claim 98 (depends on 97)

The process of claim 97, wherein the level of 14-hydroxycodeinone is decreased to less than 10 ppm.

### Claim 99 (depends on 94)

The process of claim 94, wherein the acid is hydrochloric acid.

### Claim 100 (depends on 94)

The process of claim 94, wherein the process is for preparing an oxycodone hydrochloride salt composition.

### Claim 101 (depends on 94)

The process of claim 94, wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition.

### Claim 102 (depends on 94)

The process of claim 94, wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition comprising less than 25 ppm 14-hydroxycodeinone.

### Claim 103

A process for preparing an oxycodone salt composition comprising:
salting an oxycodone free base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone and 14-hydroxycodeinone to convert the oxycodone free base composition to an oxycodone salt composition,
promoting dehydration of 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during the salting by overloading the amount of an acid during the conversion,
providing reducing conditions sufficient for the 14-hydroxycodeinone to be reduced to oxycodone,
isolating the oxycodone salt composition, and
analyzing a sample of the oxycodone salt composition for the presence of 8α,14-dihydroxy-7,8-dihydrocodeinone and 14-hydroxycodeinone,
wherein the oxycodone salt composition is substantially free of 14-hydroxycodeinone.

### Claim 104 (depends on 103)

The process of claim 103, wherein the oxycodone salt composition comprises less than 100 ppm 14-hydroxycodeinone.

### Claim 105 (depends on 104)

The process of claim 104, wherein the oxycodone salt composition comprises 0.25 ppm or more 14-hydroxycodeinone.

### Claim 106 (depends on 105)

The process of claim 105, wherein the oxycodone salt composition comprises 1 ppm or more 14-hydroxycodeinone

### Claim 107 (depends on 103)

The process of claim 103, wherein the acid is hydrochloric acid.

### Claim 108 (depends on 103)

The process of claim 103, wherein the process is for preparing an oxycodone hydrochloride salt composition.

### Claim 109 (depends on 103)

The process of claim 103, wherein the process is for preparing an oxycodone hydrochloride salt active pharmaceutical ingredient composition.
